Tempus AI Unveils AI-Powered Whole-Genome Sequencing Test to Revolutionize Precision Medicine

Tempus AI, Inc. (NASDAQ: TEM), a leading technology company in the adoption of AI to advance precision medicine and patient care, has announced the development of its first whole-genome sequencing test, xH. This innovative assay marks Tempus' entry into the whole-genome sequencing (WGS) platform, enabling clinicians to detect all clinically relevant variants and facilitating personalized therapy, particularly in hematological oncology.

The xH test, currently available for research use only (RUO) and slated for clinical availability within the next year, is designed to support Tempus' biopharma collaborators. By sequencing the whole genome, Tempus aims to provide unique insights that can only be derived from this comprehensive approach.

Tempus' xH test offers several advantages over existing targeted sequencing approaches in detecting clinically relevant variants. The WGS assay provides complete coverage of the entire genome, allowing for the detection of variants in genes not typically targeted by other sequencing methods. In a pilot study of 135 patients, the xH WGS assay demonstrated high sensitivity in detecting clinically relevant genetic alterations across various hematological malignancies, with a concordance rate of over 98.9% compared to traditional molecular methods.



The xH assay consolidates multiple tests into a single assay, making it a cost-effective and efficient tool for genomic profiling in myeloid malignancies. It can detect a broad array of mutation types, including guideline-recommended structural variants (SVs) and large copy number alterations (CNAs). This comprehensive approach enhances personalized treatment strategies by providing a robust and efficient approach to genomic profiling, enabling clinicians to make more informed decisions based on a patient's unique genetic profile.

Tempus' AI capabilities can further enhance the interpretation and clinical utility of WGS data. By leveraging its extensive multimodal dataset and advanced algorithms, Tempus can identify clinically relevant variants, predict drug response, identify patients for clinical trials, and improve diagnostic accuracy. This integration of AI with WGS data enables Tempus to provide more comprehensive, accurate, and clinically relevant insights to support personalized medicine and improve patient care.



In conclusion, Tempus AI's xH test represents a significant advancement in the field of precision medicine, offering a comprehensive and cost-effective approach to whole-genome sequencing. By combining WGS with AI capabilities, Tempus is poised to revolutionize the way clinicians detect and treat genetic disorders, ultimately improving patient outcomes and accelerating therapeutic advancements in partnership with the pharmaceutical community.